aTyr Pharma announces FDA alignment on Phase 3 study of efzofitimod in pulmonary sarcoidosis

ATYR•2026-09-24

aTyr Pharma said it aligned with the FDA on a Phase 3 study of efzofitimod in pulmonary sarcoidosis and plans to begin study-related activities in Q4 2026.

1. Study plans

aTyr Pharma announced alignment with the FDA on a Phase 3 study of efzofitimod in pulmonary sarcoidosis and said it plans to initiate study-related activities in Q4 2026.

aTyr Pharma announces FDA alignment on Phase 3 study of efzofitimod in pulmonary sarcoidosis

1. Study plans

Related News

Cellyan Biotechnology appoints Letao Zhao as independent director and compensation committee chair

Deals of the day—mergers and acquisitions

IBM expands digital banking infrastructure with Swift integration and Digital Asset Haven on-premises

Boxabl appoints Timothy Goldsmith, CPA, to board as audit committee chair

Group 1 Automotive Realty enters $190.34 million term loan agreement with Bank of America